Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Catalyst presented at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, providing a high-level corporate overview. CEO Rich Daly emphasized the company's focus on ultra-rare neuromuscular diseases and highlighted two programs: FIRDAPSE for Lambert-Eaton myasthenic syndrome and AGAMREE (a differentiated steroid) for Duchenne muscular dystrophy. The excerpt disclosed no financial metrics, guidance, regulatory updates, or launch milestones, so it is unlikely to move the stock materially in the near term.

Analysis

The core economic lever here is concentrated, cash-generative revenue tied to very small patient populations — that structure creates asymmetric outcomes: modest patient-share gains translate into high percentage upside in near-term sales, while a single manufacturing or payer disruption can crater quarterly revenue. Expect suppliers of specialized API, sterile-fill capacity and cold-chain logistics to see lumpy demand swings; a single-site outage would likely compress available supply for weeks and force steep, short-run price concessions to retain access for patients.

Competitive dynamics: the firm's non-curative steroid-like franchise competes on tolerability and convenience rather than on curative claims, which makes it defensible in the 12–36 month window but vulnerable to technology displacement (gene therapies) over 3–7 years. That creates a narrow window where EBITDA multiple re-rating or strategic M&A are plausible if management strings together predictable top-line growth and payer stability. PBMs and specialty pharmacies are second-order beneficiaries — tighter utilization controls or formulary negotiation could pressure realized net prices within two to four quarters.

Key risks and catalysts are asymmetric: watch near-term commercial metrics (sequential patient starts, refill rates, payer mix) over the next 2–3 quarters and manufacturing audit/inspection outcomes on a 0–6 month cadence. Tail risks include adverse payer rulings, a single-source manufacturing failure, or a rapid uptake of a superior DMD curative that structurally reduces addressable market over multiple years. The market may be underpricing stable cash generation but overpricing long-term franchise durability versus curative disruption; position sizing should reflect that time-decay tradeoff.

Key Decisions for Investors

• Buy CPRX call spread (9–12 month tenor): buy near-ATM calls and sell calls ~30–50% higher to finance premium. Rationale: captures 30–70% upside from sequential commercial beats with limited premium loss if patient metrics disappoint. Timeframe: 3–12 months. Risk: premium loss; reward: capped upside ~2–3x premium.
• Pair trade — long CPRX equity / short SRPT (Sarepta) equal dollar: 6–12 month horizon to isolate idiosyncratic commercial execution vs gene-therapy valuation rerating. Rationale: hedge sector beta while owning near-term cash flow vs longer-dated curative narrative. Target: 20–50% net alpha if commercial read-throughs favor CPRX; risk: both move on macro healthcare flows.
• Protective hedge: buy 3–6 month out-of-the-money puts on CPRX (small allocation ~2–4% of position) ahead of upcoming sales prints or inspections. Rationale: insures against single-event manufacturing/payer shocks that would wipe out a quarter of revenue quickly. Timeframe: 0–6 months. Cost: limited to put premium.
• M&A-oriented LEAPs: if conviction in strategic takeout within 12–36 months, buy deep ITM 18–24 month calls to capture takeover premium with less time decay. Rationale: takeover arbitrage alternative with ~2:1 reward:risk if bidding interest materializes; downside limited to option premium.